SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders

BACKGROUND: The clinical efficacy of SARS-CoV-2 vaccines according to antibody response in immunosuppressed patients such as hematological patients has not yet been established. PATIENTS AND METHODS: A prospective multicenter registry-based cohort study conducted from December 2020 to December 2021...

Descripción completa

Detalles Bibliográficos
Autores principales: Piñana, José Luis, López-Corral, Lucia, Martino, Rodrigo, Vazquez, Lourdes, Pérez, Ariadna, Martin-Martin, Gabriel, Gago, Beatriz, Sanz-Linares, Gabriela, Sanchez-Salinas, Andrés, Villalon, Lucia, Conesa-Garcia, Venancio, Olave, María T., Corona, Magdalena, Marcos-Corrales, Sara, Tormo, Mar, Hernández-Rivas, José Ángel, Montoro, Juan, Rodriguez-Fernandez, Alicia, Risco-Gálvez, Irene, Rodríguez-Belenguer, Pablo, Hernandez-Boluda, Juan Carlos, García-Cadenas, Irene, Ruiz-García, Montserrat, Muñoz-Bellido, Juan Luis, Solano, Carlos, Cedillo, Ángel, Sureda, Anna, Navarro, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077637/
https://www.ncbi.nlm.nih.gov/pubmed/35526045
http://dx.doi.org/10.1186/s13045-022-01275-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077637/
https://www.ncbi.nlm.nih.gov/pubmed/35526045
http://dx.doi.org/10.1186/s13045-022-01275-7

Ejemplares similares